Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANDROID 10 vs CARDURA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.
Selective antagonist of alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and prostate.
Male hypogonadism (primary and hypogonadotropic),Delayed puberty in males,Off-label: Androgen replacement in transgender men (masculinizing hormone therapy)
Hypertension,Benign prostatic hyperplasia
Testosterone undecanoate 750 mg (3 m L) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.
Initial: 1 mg orally once daily, titrated based on standing blood pressure response up to 16 mg daily as a single dose or divided twice daily. Maximum: 16 mg/day.
8 hours; clinical context: steady-state achieved in 2-3 days, dosing interval 8-12 hours.
Terminal elimination half-life is approximately 22 hours, allowing once-daily dosing; peak effect on blood pressure occurs at 2-6 hours post-dose.
Hepatic metabolism via CYP3A4; undergoes extensive first-pass metabolism; metabolites primarily excreted renally.
Extensively metabolized in the liver via O-demethylation and hydroxylation; CYP3A4 is the major enzyme involved.
Renal: 90% as glucuronide and sulfate conjugates, 6% as unchanged drug; fecal: 4%.
Primarily hepatic metabolism (approx. 60-70%) with biliary excretion of metabolites; renal excretion accounts for about 30-40% of the dose, mainly as metabolites with <5% unchanged drug.
97-99% bound primarily to sex hormone-binding globulin (SHBG) and albumin.
98-99% bound to plasma proteins (primarily albumin).
0.5-1.0 L/kg; indicates extensive distribution into tissues and organs.
0.5-1.0 L/kg (approximately 50-70 L in adults); indicates extensive extravascular distribution.
Oral: low (variable, ~5-20% due to first-pass metabolism); intramuscular: 100%.
Oral bioavailability is approximately 65% (range 43-81%) with minimal first-pass effect.
No specific dose adjustment required for renal impairment; monitor serum testosterone levels and clinical response. For severe renal impairment (GFR <30 m L/min), consider increased monitoring due to potential fluid retention.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, start with 0.5 mg daily and titrate cautiously due to increased sensitivity.
Contraindicated in patients with severe hepatic dysfunction (Child-Pugh class C). For mild to moderate impairment (Child-Pugh class A or B), use with caution and consider dose reduction; monitor liver function tests regularly.
Child-Pugh A: Start at 0.5 mg daily. Child-Pugh B or C: Contraindicated due to extensive hepatic metabolism.
Not recommended for use in children; safety and efficacy not established. For delayed puberty in adolescent males: testosterone enanthate 50-200 mg intramuscularly every 2-4 weeks, titrated to response, with monitoring of bone age.
Safety and efficacy not established in pediatric patients; use not recommended.
Start at low end of dosing range (e.g., testosterone cypionate 50 mg intramuscularly every 4 weeks or gel 25 mg daily) due to potential increased sensitivity and risk of prostatic hypertrophy or cardiovascular events. Monitor serum testosterone, hematocrit, and prostate-specific antigen (PSA).
Initiate at 0.5 mg daily due to increased risk of orthostatic hypotension. Titrate slowly based on tolerability and response.
None
None
Risk of hepatotoxicity; use with caution in patients with liver disease. Monitor liver function, lipid profile, and prostate-specific antigen (PSA). May cause fluid retention, gynecomastia, priapism, and sleep apnea. Not for use in women who are pregnant or breastfeeding. May accelerate growth of prostate cancer and benign prostatic hyperplasia. Androgenic effects may cause virilization in women.
Orthostatic hypotension and syncope, especially with first dose,Use with caution in patients with hepatic impairment,Risk of priapism,Intraoperative floppy iris syndrome during cataract surgery
Men with carcinoma of the prostate or breast; history of hypersensitivity to testosterone or any component; women who are pregnant or may become pregnant (risk of fetal harm); patients with severe hepatic or cardiac disease.
Hypersensitivity to doxazosin or other quinazolines
No known food interactions. However, methyltestosterone can increase appetite and cause weight gain; a balanced diet is recommended.
Avoid grapefruit and grapefruit juice as they may increase doxazosin levels. Take with food to reduce gastrointestinal upset. No other significant food interactions.
Android 10 is a combination of methyltestosterone and ethinyl estradiol. Methyltestosterone is an androgen; exposure during pregnancy, particularly during the first trimester, can cause virilization of the female fetus. Ethinyl estradiol is contraindicated in pregnancy due to risk of fetal harm. Use is contraindicated in all trimesters.
Pregnancy Category C. First trimester: No evidence of teratogenicity in animal studies; limited human data. Second/third trimesters: Potential risk of fetal hypotension and hypoxia from maternal hypotension. Avoid use in pregnancy unless benefit outweighs risk.
Methyltestosterone and ethinyl estradiol are excreted in breast milk. Methyltestosterone may cause virilization in female infants. Ethinyl estradiol may reduce milk production and quality. M/P ratio not available. Breastfeeding is contraindicated.
Excreted in human milk; M/P ratio unknown. Caution due to potential for hypotension in nursing infants. Use only if essential.
Contraindicated in pregnancy; no dosing adjustments apply. If inadvertent use occurs, discontinue immediately.
No established dose adjustments for pregnancy; use lowest effective dose due to potential for increased clearance and changes in volume of distribution.
Android 10 is a brand name for methyltestosterone, an androgen and anabolic steroid. Use is restricted to replacement therapy in males with hypogonadism or delayed puberty due to androgen deficiency. Monitor liver function due to risk of peliosis hepatis and hepatocellular carcinoma. Contraindicated in males with breast or prostate cancer. Can cause erythrocytosis; monitor hematocrit. Discontinue if signs of virilization in women or priapism in men. Use caution in elderly due to increased risk of prostatic hypertrophy.
CARDURA (doxazosin) is an alpha-1 blocker used for hypertension and benign prostatic hyperplasia (BPH). First-dose syncope is more common with immediate-release (IR) than extended-release (GITS). Start IR at 1 mg at bedtime and titrate slowly. GITS formulation minimizes orthostatic effects. Monitor blood pressure carefully in elderly patients. May cause intraoperative floppy iris syndrome (IFIS) during cataract surgery; do not stop therapy preoperatively. Avoid use in patients with orthostatic hypotension or micturition syncope.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Report signs of liver problems: yellowing of skin or eyes, dark urine, light-colored stools, abdominal pain.,Notify your doctor if you experience swelling of ankles or feet, trouble breathing, or persistent erections lasting more than 4 hours.,May cause aggressive behavior, mood swings, or depression; contact your doctor if these occur.,Do not take if you are pregnant or breastfeeding.,Keep all appointments for blood tests and liver function monitoring.
Take the first dose at bedtime to minimize dizziness. Sit or lie down if you feel lightheaded.,Avoid sudden position changes; rise slowly from sitting or lying positions.,May cause dizziness, drowsiness, or blurred vision. Do not drive until you know how CARDURA affects you.,For BPH, it may take up to 2 weeks to improve symptoms. Do not stop medication abruptly.,Inform your surgeon if you are scheduled for cataract surgery; CARDURA may affect eye surgery outcomes.,Avoid alcohol, which can worsen side effects like dizziness and low blood pressure.,For hypertension, continue regular monitoring with your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANDROID 10 vs CARDURA, answered by our medical review team.
ANDROID 10 is a Androgen that works by Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.. CARDURA is a Alpha-1 Blocker Antihypertensive that works by Selective antagonist of alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and prostate.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANDROID 10 and CARDURA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANDROID 10 is: Testosterone undecanoate 750 mg (3 m L) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.. The standard adult dose of CARDURA is: Initial: 1 mg orally once daily, titrated based on standing blood pressure response up to 16 mg daily as a single dose or divided twice daily. Maximum: 16 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANDROID 10 and CARDURA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANDROID 10 is classified as Category C. Android 10 is a combination of methyltestosterone and ethinyl estradiol. Methyltestosterone is an androgen; exposure during pregnancy, particularly during the first trimester, can . CARDURA is classified as Category C. Pregnancy Category C. First trimester: No evidence of teratogenicity in animal studies; limited human data. Second/third trimesters: Potential risk of fetal hypotension and hypoxia. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.